GlassScriptPhysician profile
Sally S Fleischman
NPI 1316087018
$1,288.50
in general payments reported to CMS, 2019-2025
24 companies · $46.01 in 2025
The $46.01 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $598 · 2020: $107 · 2021: $71.58 · 2022: $162 · 2023: $190 · 2024: $114 · 2025: $46.01.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $336 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $336.26 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $163.78 | 2019-2025 | Rexulti |
| Lilly USA, LLC | $156.45 | 2019-2024 | Mounjaro |
| Allergan, INC. | $152.82 | 2019 | |
| Glaxosmithkline, LLC. | $96.48 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $79.36 | 2020-2024 | Farxiga, Breztri |
| Novo Nordisk INC | $78.87 | 2019-2023 | Rybelsus, Ozempic |
| Celgene Corporation | $67.12 | 2019 | |
| Amgen INC. | $57.24 | 2019-2025 | |
| Abbvie INC. | $56.93 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.68 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $44.43 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.85 | 2019 | |
| Amarin Pharma, INC. | $35.57 | 2020 | |
| Abbott Laboratories | $32.74 | 2022-2023 | Freestyle Libre 3 |
| Axsome Therapeutics, INC. | $30.22 | 2024 | Auvelity |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $27.52 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $26.08 | 2019 | |
| Astellas Pharma US INC | $18.89 | 2020 | |
| Lundbeck LLC | $15.40 | 2023 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.27 | 2023 | Xifaxan, Trulance |
| Eisai INC. | $13.42 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.78 | 2023 | |
| Agile Therapeutics, INC. | $12.22 | 2021 | |
| Pfizer INC. | $11.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sally Fleischman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.